Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 1/2013

01-02-2013 | HIV/AIDS (R MacArthur, Section Editor)

HIV Drug Resistance and the Advent of Integrase Inhibitors

Authors: Peter K. Quashie, Thibault Mesplède, Mark A. Wainberg

Published in: Current Infectious Disease Reports | Issue 1/2013

Login to get access

Abstract

This review focuses on the topic of HIV integrase inhibitors that are potent antiretroviral drugs that efficiently decrease viral load in patients. However, emergence of resistance mutations against this new class of drugs represents a threat to their long-term efficacy. Here, we provide new information about the most recent mutations identified and other mutations that confer resistance to several integrase inhibitors, such as new resistance mutations—for example, G118R, R263K, and S153Y—that have been identified through in vitro selection studies with second-generation integrase strand transfer inhibitors (INSTIs). These add to the three main resistance pathways involving mutations at positions Y143, N155, and Q148. Deep sequencing, structural modeling, and biochemical analyses are methods that currently help in the understanding of the mechanisms of resistance conferred by these mutations. Although the new resistance mutations appear to confer only low levels of cross-resistance to second-generation drugs, the Q148 pathway with numerous secondary mutations has the potential to significantly decrease susceptibility to all drugs of the INSTI family of compounds.
Literature
1.
Whitney JB, Lim SY, Wainberg MA. Evolutionary mechanisms of retroviral persistence. AIDS Rev. 2011;13(4):234–9.PubMed
2.
Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med. 2011;365(7):637–46.PubMedCrossRef
3.
Delelis O, Carayon K, Saib A, Deprez E, Mouscadet JF. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology. 2008;5:114.PubMedCrossRef
4.
Li X, Krishnan L, Cherepanov P, Engelman A. Structural biology of retroviral DNA integration. Virology. 2011;411(2):194–205.PubMedCrossRef
5.
Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287(5453):646–50.PubMedCrossRef
6.
Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012;10(4):279–90.PubMedCrossRef
7.
Schafer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. Ann Pharmacother. 2010;44(1):145–56.PubMedCrossRef
8.
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355–65.PubMedCrossRef
9.
Briz V, Garrido C, Poveda E, Morello J, Barreiro P, de Mendoza C, et al. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses. 2009;25(2):225–7.PubMedCrossRef
10.
Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, et al. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci. 2011;1222:83–9.PubMedCrossRef
11.
• Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339–54. This study was the first to demonstrate the safety and efficacy of a HIV integrase inhibitor in a large randomized phase 3 clinical trial. Follow-up data have documented the superiority of Ralegravir versus a NNRTI, efavirenz, over a period of 5 years in patients also receiving the double nucleoside combination of TDF/FTC.PubMedCrossRef
12.
Wills T, Vega V. Elvitegravir: a once-daily inhibitor of HIV-1 integrase. Expert Opin Investig Drugs. 2012;21(3):395–401.PubMedCrossRef
13.
Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs. 2012;21(4):523–30.PubMedCrossRef
14.
Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 2008;80(2):213–22.PubMedCrossRef
15.
Nakahara K, Wakasa-Morimoto C, Kobayashi M, Miki S, Noshi T, Seki T, et al. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res. 2009;81(2):141–6.PubMedCrossRef
16.
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010;50(4):605–12.PubMedCrossRef
17.
Goethals O, Van Ginderen M, Vos A, Cummings MD, Van Der Borght K, Van Wesenbeeck L, et al. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Res. 2011;91(2):167–76.PubMedCrossRef
18.
Bar-Magen T, Sloan RD, Faltenbacher VH, Donahue DA, Kuhl BD, Oliveira M, et al. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology. 2009;6:103.PubMedCrossRef
19.
Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol. 2010;84(18):9210–6.PubMedCrossRef
20.
Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, et al. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob Agents Chemother. 2011;55(1):321–5.PubMedCrossRef
21.
Song I, Borland J, Min S, Lou Y, Chen S, Patel P, et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother. 2011;55(7):3517–21.PubMedCrossRef
22.
Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254–8.PubMedCrossRef
23.
Min S, Sloan L, Dejesus E, Hawkins T, McCurdy L, Song I, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. Aids. 2011;25(14):1737–45.PubMedCrossRef
24.
Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813–21.PubMedCrossRef
25.
Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, et al. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology. 2010;402(2):338–46.PubMedCrossRef
26.
Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor Dolutegravir (S/GSK1349572). Mol Pharmacol 2011.
27.
Seki T, Kobayashi M, Wakasa-Morimoto C, Yoshinaga T, Sato A, Fujiwara T, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. 17th CROI, Conference on retroviruses and opportunistic infections, San Francisco, CA. 2010.
28.
• Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor Dolutegravir. J Virol. 2012;86(5):2696–705. This study was the first to definitively demonstrate that resistance against dolutegravir may be likely to occur, based on a R263K mutation in the HIV integrase gene.PubMedCrossRef
29.
Krishnan L, Li X, Naraharisetty HL, Hare S, Cherepanov P, Engelman A. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A. 2010;107(36):15910–5.PubMedCrossRef
30.
Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature. 2010;464(7286):232–6.PubMedCrossRef
31.
Cherepanov P, Maertens GN, Hare S. Structural insights into the retroviral DNA integration apparatus. Curr Opin Struct Biol. 2011;21(2):249–56.PubMedCrossRef
32.
Maertens GN, Hare S, Cherepanov P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature. 2010;468(7321):326–9.PubMedCrossRef
33.
Espeseth AS, Felock P, Wolfe A, Witmer M, Grobler J, Anthony N, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A. 2000;97(21):11244–9.PubMedCrossRef
34.
Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A. 2010;107(46):20057–62.PubMedCrossRef
35.
Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A. 2002;99(10):6661–6.PubMedCrossRef
36.
Bacchi A, Carcelli M, Compari C, Fisicaro E, Pala N, Rispoli G, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407–20.PubMedCrossRef
37.
Bacchi A, Carcelli M, Compari C, Fisicaro E, Pala N, Rispoli G, et al. HIV-1 IN strand transfer chelating inhibitors: a focus on metal binding. Mol Pharm. 2011;8(2):507–19.PubMedCrossRef
38.
Johnson AA, Santos W, Pais GC, Marchand C, Amin R, Burke Jr TR, et al. Integration requires a specific interaction of the donor DNA terminal 5'-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J Biol Chem. 2006;281(1):461–7.PubMedCrossRef
39.
Jayappa KD, Ao Z, Yang M, Wang J, Yao X. Identification of critical motifs within HIV-1 integrase required for importin alpha3 interaction and viral cDNA nuclear import. J Mol Biol. 2011;410(5):847–62.PubMedCrossRef
40.
Metifiot M, Vandegraaff N, Maddali K, Naumova A, Zhang X, Rhodes D, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. Aids. 2011;25(9):1175–8.PubMedCrossRef
41.
Kawonga M, Blanchard K, Cooper D, Cullingworth L, Dickson K, Harrison T, et al. Integrating medical abortion into safe abortion services: experience from three pilot sites in South Africa. J Fam Plann Reprod Health Care. 2008;34(3):159–64.PubMedCrossRef
42.
• Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55(10):4552–9. This article shows that dolutegravir is likely to be active on a once-daily basis due to the fact that it binds almost irreversibly to the HIV integrase molecule.PubMedCrossRef
43.
Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006;5(9):730–9.PubMedCrossRef
44.
Oliveira M, Brenner BG, Wainberg MA. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol. 2009;485:427–33.PubMedCrossRef
45.
Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008;82(21):10366–74.PubMedCrossRef
46.
Jones G, Ledford R, Yu F, Chen X, Miller MD, Tsiang M, et al. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). 14th CROI, Conference on Retroviruses and opportunistic infections, Los Angeles, California, 2007.
47.
Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008;82(2):764–74.PubMedCrossRef
48.
Codoner FM, Pou C, Thielen A, Garcia F, Delgado R, Dalmau D, et al. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res. 2010;88(3):281–6.PubMedCrossRef
49.
Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, et al. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis. 2012;205(4):557–67.PubMedCrossRef
50.
Winters B, Lloyd RJ, Miller M, Holodniy M. Evolution of IN inhibitor resistance mutations in patients failling elvitegravir-containing regimens. 19th CROI, Conference on retroviruses and opportunistic infections, Seattle, WA, 2012. Abstract: p. 701.
51.
Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. Aids. 2009;23(4):455–60.PubMedCrossRef
52.
Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Belec L, Weiss L, et al. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med. 2008;9(9):765–70.PubMedCrossRef
53.
Fransen S, Karmochkine M, Huang W, Weiss L, Petropoulos CJ, Charpentier C. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother. 2009;53(10):4522–4.PubMedCrossRef
54.
Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother. 2009;63(4):795–804.PubMedCrossRef
55.
Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist Updat. 2010;13(4–5):139–50.PubMedCrossRef
56.
Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203(9):1204–14.PubMedCrossRef
57.
Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, et al. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother. 2011;66(12):2827–30.PubMedCrossRef
58.
Sato A, Seki T, Kobayashi M, Yoshinaga T, Fujiwara T, Underwood M, et al. In vitro passage of drug resistant HIV-1 against a next generation integrase inhibitor (INI), S/GSK1349572. 49th ICAAC, San Francisco, CA. 2009.
59.
Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, McColl DJ, et al. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res. 2012;93(2):288–96.PubMedCrossRef
60.
Canducci F, Ceresola ER, Boeri E, Spagnuolo V, Cossarini F, Castagna A, et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204(11):1811–5.PubMedCrossRef
61.
Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir in combination therapy exhibits rapid and sustained antiviral response in ARV-naïve adults: 96-week results from SPRING-1 (ING112276). 19th CROI, Conference on retroviruses and opportunistic infections, Seattle, WA, 2012. Abstract: p. 102LB.
62.
van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–8.PubMedCrossRef
63.
Enron J, Kumar P, Lazzarin A, Richmond G, Soriano V, Huang J, et al. DTG in Subjects with HIV Exhibiting RAL Resistance: Functional Monotherapy Results of VIKING Study Cohort II. 18th CROI, Conference on retroviruses and opportunistic infections, Boston, MA, 2011. Abstract: p. 151LB.
64.
Kobayashi M, Seki T, Yoshinaga T, Sato A, Fujiwara T, Underwood M, et al. Antiviral Activity in vitro of the INI, Dolutegravir, against Raltegravir-resistant HIV-2 Mutants. 19th CROI, Conference on retroviruses and opportunistic infections, Seattle, WA, 2012. Abstract: p. 691.
65.
Gupta SP, Nagappa AN. Design and development of integrase inhibitors as anti-HIV agents. Curr Med Chem. 2003;10(18):1779–94.PubMedCrossRef
66.
Sluis-Cremer N, Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur J Biochem. 2002;269(21):5103–11.PubMedCrossRef
67.
Maurin C, Bailly F, Cotelle P. Structure-activity relationships of HIV-1 integrase inhibitors–enzyme-ligand interactions. Curr Med Chem. 2003;10(18):1795–810.PubMedCrossRef
68.
Singh SB, Jayasuriya H, Salituro GM, Zink DL, Shafiee A, Heimbuch B, et al. The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acid-hydrolysis products of chloropeptin I. J Nat Prod. 2001;64(7):874–82.PubMedCrossRef
69.
Jing N, Xu X. Rational drug design of DNA oligonucleotides as HIV inhibitors. Curr Drug Targets Infect Disord. 2001;1(2):79–90.PubMedCrossRef
70.
Brigo A, Mustata GI, Briggs JM, Moro S. Discovery of HIV-1 integrase inhibitors through a novel combination of ligand and structure-based drug design. Med Chem. 2005;1(3):263–75.PubMedCrossRef
71.
de Soultrait VR, Desjobert C, Tarrago-Litvak L. Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase. Curr Med Chem. 2003;10(18):1765–78.PubMedCrossRef
72.
••Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287(5453):646–50. This article was the first to demonstrate that the development of integrase strand transfer inhibitors was possible and opened up the field of anti-integrase drug development.PubMedCrossRef
73.
Reinke R, Lee DJ, Robinson WE. Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid. Antimicrob Agents Chemother. 2002;46(10):3301–3.PubMedCrossRef
74.
Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol. 2009;49:377–94.PubMedCrossRef
75.
Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR, et al. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem. 2002;277(15):12596–603.PubMedCrossRef
76.
FDA. FDA approval of Isentress (raltegravir). 2007 [cited 2011 07/08/2011].
77.
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010;50(4):605–12.PubMedCrossRef
78.
Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T, Schader SM, Wainberg MA. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother. 2010;54(3):1047–54.PubMedCrossRef
79.
Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369(9569):1261–9.PubMedCrossRef
80.
Iwamoto M. Rifampin (RIF) modestly reduces plasma levels of MK-0518, in 8th Int. Congr. Drug Therapy in HIV Infection (HIV-8), L.S. Wenning LA, Kost JT, Mangin E, et al, editors. 2006: Glasgow, Scotland.
81.
Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46(2):125–33.PubMedCrossRef
82.
Eron JJ, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis, 2011.
83.
Vispo E, Barreiro P, Maida I, Mena A, Blanco F, Rodríguez-Novoa S, et al. Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. HIV Clin Trials. 2010;11(4):197–204.PubMedCrossRef
84.
Lanzafame M, Hill A, Lattuada E, Calcagno A, Bonora S. Raltegravir: is a 400 mg once-daily dose enough? J Antimicrob Chemother. 2010;65(3):595–7.PubMedCrossRef
85.
Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008;52(4):1351–8.PubMedCrossRef
86.
Garrido C, de Mendoza C, Soriano V. Resistance to integrase inhibitors. Enferm Infecc Microbiol Clin. 2008;26 Suppl 12:40–6.PubMedCrossRef
87.
Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, et al. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS. 2010;24(14):2171–9.PubMedCrossRef
88.
Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 2009;37(4):1193–201.PubMedCrossRef
89.
Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010;18(5):156–63.PubMed
90.
Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr. 2010;55(2):148–55.PubMedCrossRef
91.
Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, et al. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect. 2011;17(6):928–34.PubMedCrossRef
92.
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355–65.PubMedCrossRef
93.
Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203(9):1204–14.PubMedCrossRef
94.
Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375(9712):396–407.PubMedCrossRef
95.
Klibanov OM. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs. 2009;10(2):190–200.PubMed
96.
Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem. 2006;49(5):1506–8.PubMedCrossRef
97.
Matsuzaki Y. JTK-303/GS 9137, a Novel Small-molecule Inhibitor of HIV-1 Integrase: Anti-HIV Activity Profile and Pharmacokinetics in Animals. in 13th Conference on Retroviruses and Opportunistic Infections. 2006. Denver, Colorado, USA.
98.
Annonymous. Single-tablet Quad regimen achieves high rate of virologic suppression. AIDS Patient Care STDS, 2010. 24(3): p. 197.
99.
Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011;50(4):229–44.PubMedCrossRef
100.
Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther. 2009;85(1):64–70.PubMedCrossRef
101.
Isao K, Ishikawa T, Ishibashi M, Irie S, Kakee A, T. Japan Tobacco Inc., et al. Clinical Pharmacology Research Clinic, Japan. Safety and Pharmacokinetics of Single Oral Dose of JTK-303/GS-9137, a Novel HIV Integrase Inhibitor, in Healthy Volunteers. in 13th Conference on Retroviruses and Opportunistic Infections. 2006. Denver, Colorado, USA.
102.
Elion R, Gathe J, Rashburn B, et al. The single-tablet regimen elvitegravir/cobicstat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; "QUAD") maintains a high rate of virologic supression, and cobicstat (COBI) is an effective pharmacoenhancer through 48 weeks. in 50th International Conference on Antimicrobial Agents and Chemotherapy. 2010. Boston, Ma, USA.
103.
Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010;201(6):814–22.PubMedCrossRef
104.
Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008;82(21):10366–74.PubMedCrossRef
105.
Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, et al. Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus Raltegravir in Treatment-Naïve HIV-1-infected Patients (ACTG A5262). AIDS, 2011.
106.
Métifiot M, Vandegraaff N, Maddali K, Naumova A, Zhang X, Rhodes D, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS. 2011;25(9):1175–8.PubMedCrossRef
107.
Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008;82(2):764–74.PubMedCrossRef
108.
Dicker IB, Terry B, Lin Z, Li Z, Bollini S, Samanta HK, et al. Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem. 2008;283(35):23599–609.PubMedCrossRef
109.
McColl DJ, Fransen S, Gupta S, et al. Basic Principles and Clinical Implications, in XVI International HIV Drug Resistance Workshop. 2007.
110.
Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS. 2009;23(4):455–60.PubMedCrossRef
111.
Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs. 2008;13(2):213–25.PubMedCrossRef
112.
Vacca J, Wai J, Fisher T, Embrey M, Hazuda D, Miller M, et al. Discovery of MK-2048 – subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitor, in 4th International AIDS Society's Conference on HIV Pathogenesis, Treatment and Prevention. 2007: Sydney, Australia.
113.
Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, et al. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob Agents Chemother. 2011;55(1):321–5.PubMedCrossRef
114.
Pandey KK, Bera S, Vora AC, Grandgenett DP. Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors. Biochemistry. 2010;49(38):8376–87.PubMedCrossRef
115.
Goethals O, Van Ginderen M, Vos A, Cummings MD, Van Der Borght K, Van Wesenbeeck L, et al. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Res. 2011;91(2):167–76.PubMedCrossRef
116.
Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol. 2010;84(18):9210–6.PubMedCrossRef
117.
118.
Seegulam ME, Ratner L. Integrase inhibitors effective against human T-cell leukemia virus type 1. Antimicrob Agents Chemother. 2011;55(5):2011–7.PubMedCrossRef
119.
Eron J, Livrozet J, Mortal P, et al. Activity of integrase inhibitor S/GSK9572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of VIKING Study, in 10th International Conference on Drug Therapy in HIV Infection. 2010: Glasgow, Scotland.
120.
Tomokazu Yoshinaga MK-K, Seki T, Ishida K, Akihisa E, Kobayashi M, Sato A, et al. Strong Inhibition of Wild-Type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572, in International HIV & Hepatitis Virus Drug Resistance Workshop. 2010: Dubrovnik, Croatia.
121.
Bar-Magen T, Sloan RD, Faltenbacher VH, Donahue DA, Kuhl BD, Oliveira M, et al. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology. 2009;6:103.PubMedCrossRef
122.
123.
Seki T, Kobayashi, K, Wakasa-Morimoto C, Yoshinaga T, Sato A, Fujiwara T, et al. No Impact of HIV Integrase Polymorphisms at Position 101 and 124 on in vitro Resistance Isolation with Dolutegravir (DTG, S/GSK1349572), A Potent Next Generation HIV Integrase Inhibitor, in 17th International Conference on Retroviruses and Opportunistic Infections. 2010: San Francisco, California.
124.
Underwood M, Brian J, Sato A, et al. S/GSK1349572: A Next Generation Integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients Experiencing Virologic Failure while on Raltegravir Therapy, in 5th International AIDS Society's Conference on HIV Pathogenesis. 2009.
125.
Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813–21.PubMedCrossRef
126.
Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254–8.PubMedCrossRef
127.
Lalezari J, Sloan L, DeJesus E, Hawkins E, McCurdy L, Song I, et al. Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Naïve HIV-1-Infected Patients: ING111521 Protocol, in 5th International AIDS Society's Conference on HIV Pathogenesis. 2009: Cape Town, South Africa.
128.
Min S, Sloan L, Dejesus E, Hawkins T, McCurdy L, Song I, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25(14):1737–45.PubMedCrossRef
129.
Rockstroh J, Felizarta F, Maggiolo FF, Pulido F, Stellbrink HJ, Tsybakova O, et al. Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276), in 10th International Conference on Drug Therapy in HIV Infection. 2010: Glasgow, Scotland.
130.
Jones G, Ledford R, Yu F, Miller M, Tsiang M, McColl D. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). . in 14th Conference on Retroviruses and Opportunistic Infections. 2007. Los Angeles, CA.
131.
Wainberg MA, Quashie PK, Han Y-S, Singhroy DN, Oliviera M, Moisi D, et al. Dolutegravir selects for R263K mutation in Subtype B and AG but not subtype C integrase enzymes. in 4th International Conference on Retroviral Integration. 2011. Siena, Italy.
132.
Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than Raltegravir and Elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55(10):4552–9.PubMedCrossRef
133.
Grobler JA, McKenna PM, Ly S, et al. Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitors. in 10th International Conference on Clinical Pharmacology of HIV Therapy. 2009. Amsterdam, Netherlands.
134.
Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, et al. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - impact of HIV subtypes and prior raltegravir experience. Antiviral Res. 2011;90(3):164–7.PubMedCrossRef
135.
Malet I, Wirden M, Fourati S, Armenia D, Masquelier B, Fabeni L, et al. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. J Antimicrob Chemother. 2011;66(7):1481–3.PubMedCrossRef
136.
O’Neal R. Dolutegravir: A new integrase inhibitor in development. 2011 [cited 2011 20/09/2011].
137.
Min S, DeJesus E, McCurdy L, et al. Early Studies Demonstrate Potent Activity and Safety of Experimental Integrase Inhibitor S/GSK1265744, in 49th Interscience Conference on Antimicrobials and Chemotherapy. 2009: San Francisco, USA.
138.
139.
Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature. 2010;464(7286):232–6.PubMedCrossRef
140.
Hare S, Smith SJ, Métifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor Dolutegravir (S/GSK1349572). Mol Pharmacol. 2011;80(4):565–72.PubMedCrossRef
141.
Krishnan L, Li X, Naraharisetty HL, Hare S, Cherepanov P, Engelman A. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A. 2010;107(36):15910–5.PubMedCrossRef
142.
Cherepanov P, Maertens GN, Hare S. Structural insights into the retroviral DNA integration apparatus. Curr Opin Struct Biol. 2011;21(2):249–56.PubMedCrossRef
143.
Hall LH. A structure-information approach to the prediction of biological activities and properties. Chem Biodivers. 2004;1(1):183–201.PubMedCrossRef
144.
Liao C, Nicklaus MC. Computer tools in the discovery of HIV-1 integrase inhibitors. Future Med Chem. 2010;2(7):1123–40.PubMedCrossRef
145.
Egbertson MS, Wai JS, Cameron M, Hoerrner RS. In: Kazmierski WM, editor. Discovery of MK-0536: A potential second-generation HIV-1 integrase strand transfer inhibitor with a high genetic barrier to mutation, in antiviral drugs: From basic discovery through clinical trials. Hoboken: Wiley; 2011.
146.
Métifiot M, Johnson B, Smith S, Zhao XZ, Marchand C, Burke T, et al. MK-0536 inhibits HIV-1 integrases resistant to raltegravir. Antimicrob Agents Chemother, 2011.
147.
LLC, I., Terephthalamate compounds and compositions, and their use as HIV integrase inhibitors. 2007.
148.
Pace P, Di Francesco ME, Gardelli C, Harper S, Muraglia E, Nizi E, et al. Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. J Med Chem. 2007;50(9):2225–39.PubMedCrossRef
149.
Muraglia E, Kinzel O, Gardelli C, Crescenzi B, Donghi M, Ferrara M, et al. Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors. J Med Chem. 2008;51(4):861–74.PubMedCrossRef
150.
Telvekar VN, Patel KN. Pharmacophore development and docking studies of the hiv-1 integrase inhibitors derived from N-methylpyrimidones, Dihydroxypyrimidines, and bicyclic pyrimidinones. Chem Biol Drug Des. 2011;78(1):150–60.PubMedCrossRef
151.
Johnson TW, Tanis SP, Butler SL, Dalvie D, Delisle DM, Dress KR, et al. Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors. J Med Chem. 2011;54(9):3393–417.PubMedCrossRef
152.
Wai JS, Kim B, Fisher TE, Zhuang L, Embrey MW, Williams PD, et al. Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors. Bioorg Med Chem Lett. 2007;17(20):5595–9.PubMedCrossRef
153.
Toropova AP, Toropov AA, Benfenati E, Gini G. Simplified molecular input-line entry system and International Chemical Identifier in the QSAR analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors. Chem Biol Drug Des. 2011;77(5):343–60.PubMedCrossRef
154.
Nagasawa JY, Song J, Chen H, Kim HW, Blazel J, Ouk S, et al. 6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors. Bioorg Med Chem Lett. 2011;21(2):760–3.PubMedCrossRef
155.
Van Maele B, Busschots K, Vandekerckhove L, Christ F, Debyser Z. Cellular co-factors of HIV-1 integration. Trends Biochem Sci. 2006;31(2):98–105.PubMedCrossRef
156.
157.
Zamborlini A, Coiffic A, Beauclair G, Delelis O, Paris J, Koh Y, et al. Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect. J Biol Chem. 2011;286(23):21013–22.PubMedCrossRef
158.
Terreni M, Valentini P, Liverani V, Gutierrez MI, Di Primio C, Di Fenza A, et al. GCN5-dependent acetylation of HIV-1 integrase enhances viral integration. Retrovirology. 2010;7:18.PubMedCrossRef
159.
Buzon MJ, Seiss K, Weiss R, Brass AL, Rosenberg ES, Pereyra F, et al. Inhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers. J Virol. 2011;85(18):9646–50.PubMedCrossRef
160.
Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol. 2010;6(6):442–8.PubMedCrossRef
161.
McNeely M, Hendrix J, Busschots K, Boons E, Deleersnijder A, Gerard M, et al. In vitro DNA tethering of HIV-1 integrase by the transcriptional coactivator LEDGF/p75. J Mol Biol. 2011;410(5):811–30.PubMedCrossRef
162.
De Luca L, Ferro S, Gitto R, Barreca ML, Agnello S, Christ F, et al. Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg Med Chem. 2010;18(21):7515–21.PubMedCrossRef
163.
Madlala P, Gijsbers R, Christ F, Hombrouck A, Werner L, Mlisana K, et al. Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression. AIDS. 2011;25(14):1711–9.PubMedCrossRef
164.
Meehan AM, Saenz DT, Morrison J, Hu C, Peretz M, Poeschla EM. LEDGF dominant interference proteins demonstrate prenuclear exposure of HIV-1 integrase and synergize with LEDGF depletion to destroy viral infectivity. J Virol. 2011;85(7):3570–83.PubMedCrossRef
165.
De Luca L, Ferro S, Morreale F, Chimirri A. Inhibition of the interaction between HIV-1 integrase and its cofactor LEDGF/p75: a promising approach in anti-retroviral therapy. Mini Rev Med Chem. 2011;11(8):714–27.PubMedCrossRef
166.
De Luca L, Ferro S, Morreale F, De Grazia S, Chimirri A. Inhibitors of the interactions between HIV-1 IN and the cofactor LEDGF/p75. ChemMedChem. 2011;6(7):1184–91.PubMedCrossRef
167.
Fenwick C, Bethell R, Cordingley M, Edwards P, Quinson A-M, Robinson P, et al. BI 224436, a Non-Catalytic Site Integrase Inhibitor, is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1. in 51st Interscience Conference on Antimicrobials and Chemotherapy. 2011. Chicago, IL, USA.
168.
Aslanyan S, Ballow C, Sabo JP, Habeck J, Roos D, MacGregor TR, et al. Safety and pharmacokinetics (PK) of single rising oral doses of a novel HIV integrase inhibitor in healthy volunteers. in 51st Interscience Conference on Antimicrobials and Chemotherapy. 2011. Chicago, IL, USA
169.
Tang J, Maddali K, Dreis CD, Sham YY, Vince R, Pommier Y, et al. N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase. ACS Med Chem Lett. 2011;2(1):63–7.PubMedCrossRef
170.
Wang Z, Tang J, Salomon CE, Dreis CD, Vince R. Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase. Bioorg Med Chem. 2010;18(12):4202–11.PubMedCrossRef
171.
Di Santo R. Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. Curr Med Chem. 2011;18(22):3335–42.PubMedCrossRef
172.
Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, et al. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol. 2011;83(5):751–9.PubMedCrossRef
173.
Loizidou EZ, Kousiappa I, Zeinalipour-Yazdi CD, Van de Vijver DA, Kostrikis LG. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses. Biochemistry. 2009;48(1):4–6.PubMedCrossRef
174.
Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, et al. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother, 2011.
175.
Dicker IB, Terry B, Lin Z, Li Z, Bollini S, Samanta HK, et al. Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem. 2008;283(35):23599–609.PubMedCrossRef
176.
Hazuda DJ. Resistance to inhibitors of the human immunodeficiency virus type 1 integration. Braz J Infect Dis. 2010;14(5):513–8.PubMed
177.
Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194 Suppl 1:S51–8.PubMedCrossRef
Metadata
Title
HIV Drug Resistance and the Advent of Integrase Inhibitors
Authors
Peter K. Quashie
Thibault Mesplède
Mark A. Wainberg
Publication date
01-02-2013
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 1/2013
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-012-0305-1

Other articles of this Issue 1/2013

Current Infectious Disease Reports 1/2013 Go to the issue

Hot Topic

Overview of the XIX International AIDS Conference

Intra-abominal Infections, Hepatitis, and Gastroenteritis (D Bobak, Section Editor)

Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli

HIV/AIDS (R MacArthur, Section Editor)

The Immune Reconstitution Inflammatory Syndrome: A Clinical Update

Intra-abdominal Infections, Hepatitis, and Gastroenteritis (D Bobak, Section Editor)

Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: What’s New?

HIV/AIDS (R MacArthur, Section Editor)

HCV Enters the Twenty-First Century

HIV/AIDS (R MacArthur, Section Editor)

Neurologic Complications and Considerations in HIV-Infected Persons
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits